Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted an aggregate of 143,500 restricted stock units and options to purchase 37,000 shares to 24 newly hired employees as a material inducement to employment. The awards were approved by the Compensation Committee under the 2022 Inducement Plan, with both RSUs and options vesting over four years.
Key figures
- New hires
- 24
- Rsus granted
- 143500
- Exercise price
- 25.94
- Options granted
- 37000
- Vesting term years
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.